Board of Directors
Jan Törnell
Born: 1960
Education: MD and PhD in Physiology, University of Gothenburg
Other assignments: CEO and board member of AB Innoext. Chairman of Glactone Pharma AB and Glactone Pharma Development AB, board member of Abliva AB and Diaprost AB
Work experience: Former Vice President of Global Strategy for AstraZeneca Oncology & Infection. Professor of Physiology at the Sahlgrenska Academy, University of Gothenburg. Partner in P.U.L.S. and member of the investment committee. Associate professor in Physiology, Gothenburg University.
Holdings: 52 909 shares, 0 warrants
Independent in relation to LIDDS AB (publ), its management and the principal shareholders
David Bejker
Born: 1975
Education: MSc from the Stockholm School of Economics
Other assignments: CEO of Affibody Medical AB and board member of Abliva AB and Amylonix AB
Work experience: CEO of Affibody Medical AB, a company that develops innovative protein drugs, since 2008. Previously at HealthCap, a specialized life science investor.
Holdings: 5 624 shares, 0 warrants
Independent in relation to LIDDS AB (publ), its management and the principal shareholders
Maria Forss
Born: 1972
Education: Master’s degree in Economics from the School of Business, Economics and Law at Gothenburg University and Concordia University, Montreal. Executive education at Stanford University, USA. Certified board member via Styrelseinstitutet and advanced board training via StyrelseAkademin
Other assignments: Senior Vice President Consumables Division, Vitrolife
Work experience: Vice President Business Development and Global Marketing at Vitrolife. Board member of Oncorena AB. Head of Business Development of Aquilion (former P.U.L.S.), CEO Duocort Pharma and management roles within Astra Zeneca.
Holdings: 26 186 shares, 0 warrants
Independent in relation to LIDDS AB (publ), its management and the principal shareholders
Daniel Lifveredson
Born: 1976
Education: Master of Science in Industrial Engineering and Management, Chalmers University of Technology in Gothenburg
Other assignments: CEO and owner of Excore AB
Work experience: Worked with Excore as a base since 1998. Excore is active in advising corporate transactions in the segment of medium-sized companies. Long experience in international business. In addition to Excore, Daniel Lifveredson is involved as a partner in a number of businesses.
Holdings: 2 640 929 shares, 0 warrants
Independent in relation to LIDDS AB (publ), its management and the principal shareholders
Johan Lund
Born: 1957
Education: MD/PhD Karolinska Institute, Stockholm.
Other assignments: Co-Founder of KyNexis Medicine Development AB and founder of MBS Pharma, CSO and Chairman of the Board of Aqilion, Chairman of the Board of NEOGAP Therapeutics AB, board member and chairman of the remuneration committee of Olink Holding (Nasdaq NYC), board member of Genagon Therapeutics AB and Pelago Bioscience AB.
Work Experience: Former VP of Immunology & Inflammation Research & Early Development, Celgene; SVP and CSO of Immunology & Inflammation, Pfizer; VP of CNS & Pain Research, AstraZeneca and VP Respiratory & Inflammation Research, AstraZeneca. Professor & Chairman, Department of Anatomy & Cell Biology, Medical Faculty, University of Bergen; Associate Professor, Department of Medical Nutrition, Karolinska Institute.
Holdings: 0 Shares
Independent in relation to LIDDS AB (publ), its management and the principal shareholders
Max Mitteregger
Born: 1963
Education: Economist
Other assignments: CEO Galba Holding AB
Work Experience: Worked as an Institutional Broker at Carnegie and co-founder of ABGSC. Since 2005 founder of MMKAP AS and manager of the hedge fund Gladiator
Holdings: 750,000 shares
Independent in relation to LIDDS AB (publ), its management and the principal shareholders